📣 VC round data is live. Check it out!
- Public Comps
- Tenaya Therapeutics
Tenaya Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Tenaya Therapeutics and similar public comparables like ProQR Therapeutics, Protalix, Orthocell, AN2 Therapeutics and more.
Tenaya Therapeutics Overview
About Tenaya Therapeutics
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
Founded
2016
HQ

Employees
97
Website
Financials (LTM)
EV
$83M
Valuation Multiples
Start free trialTenaya Therapeutics Financials
Tenaya Therapeutics reported last 12-month revenue of $3M and negative EBITDA of ($78M).
In the same LTM period, Tenaya Therapeutics generated $1M in gross profit, ($78M) in EBITDA losses, and had net loss of ($89M).
Revenue (LTM)
Tenaya Therapeutics P&L
In the most recent fiscal year, Tenaya Therapeutics reported revenue of — and EBITDA of ($85M).
Tenaya Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.
Financial data powered by Morningstar, Inc.
Tenaya Therapeutics Stock Performance
Tenaya Therapeutics has current market cap of $173M, and enterprise value of $83M.
Market Cap Evolution
Tenaya Therapeutics' stock price is $0.80.
Tenaya Therapeutics share price increased by 15.4% in the last 30 days, and by 73.3% in the last year.
Tenaya Therapeutics has an EPS (earnings per share) of $-0.42.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $83M | $173M | 12.9% | 15.4% | 42.1% | 73.3% | $-0.42 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTenaya Therapeutics Valuation Multiples
Tenaya Therapeutics trades at 29.2x EV/Revenue multiple, and (1.1x) EV/EBITDA.
EV / Revenue (LTM)
Tenaya Therapeutics Financial Valuation Multiples
As of May 5, 2026, Tenaya Therapeutics has market cap of $173M and EV of $83M.
Tenaya Therapeutics has a P/E ratio of (1.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tenaya Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Tenaya Therapeutics Margins & Growth Rates
Tenaya Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Tenaya Therapeutics Operational KPIs
Tenaya Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Tenaya Therapeutics Competitors
Tenaya Therapeutics competitors include ProQR Therapeutics, Protalix, Orthocell, AN2 Therapeutics, Vytrus Biotech, Panion & Bf Biotech, Tetratherix, Tiziana Life Sciences, Satellos Bioscience and Hyloris Pharmaceuticals.
Most Tenaya Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 4.5x | 3.9x | (1.8x) | (2.3x) | |||
| 2.8x | 2.4x | (50.7x) | — | |||
| 23.1x | 16.0x | (26.7x) | (17.6x) | |||
| — | — | (3.1x) | — | |||
| 17.1x | 15.7x | 34.5x | 31.2x | |||
| 2.8x | — | 12.9x | — | |||
| — | 46.3x | — | (29.8x) | |||
| — | — | (10.2x) | — | |||
This data is available for Pro users. Sign up to see all Tenaya Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Tenaya Therapeutics Funding History
Before going public, Tenaya Therapeutics raised $248M in total equity funding, across 3 rounds.
Last private valuation of Tenaya Therapeutics was $210M, after raising $106M in March 2021 from Casdin Capital, Fidelity, GV, and 4 other investors.
Tenaya Therapeutics Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tenaya Therapeutics
| When was Tenaya Therapeutics founded? | Tenaya Therapeutics was founded in 2016. |
| Where is Tenaya Therapeutics headquartered? | Tenaya Therapeutics is headquartered in United States. |
| How many employees does Tenaya Therapeutics have? | As of today, Tenaya Therapeutics has over 97 employees. |
| Who is the CEO of Tenaya Therapeutics? | Tenaya Therapeutics' CEO is Faraz Ali. |
| Is Tenaya Therapeutics publicly listed? | Yes, Tenaya Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Tenaya Therapeutics? | Tenaya Therapeutics trades under TNYA ticker. |
| When did Tenaya Therapeutics go public? | Tenaya Therapeutics went public in 2021. |
| Who are competitors of Tenaya Therapeutics? | Tenaya Therapeutics main competitors include ProQR Therapeutics, Protalix, Orthocell, AN2 Therapeutics, Vytrus Biotech, Panion & Bf Biotech, Tetratherix, Tiziana Life Sciences, Satellos Bioscience, Hyloris Pharmaceuticals. |
| What is the current market cap of Tenaya Therapeutics? | Tenaya Therapeutics' current market cap is $173M. |
| What is the current revenue of Tenaya Therapeutics? | Tenaya Therapeutics' last 12 months revenue is $3M. |
| What is the current revenue growth of Tenaya Therapeutics? | Tenaya Therapeutics revenue growth (NTM/LTM) is 92%. |
| What is the current EV/Revenue multiple of Tenaya Therapeutics? | Current revenue multiple of Tenaya Therapeutics is 29.2x. |
| Is Tenaya Therapeutics profitable? | No, Tenaya Therapeutics is not profitable. |
| What is the current EBITDA of Tenaya Therapeutics? | Tenaya Therapeutics has negative EBITDA and is not profitable. |
| What is Tenaya Therapeutics' EBITDA margin? | Tenaya Therapeutics' last 12 months EBITDA margin is (2719%). |
| What is the current EV/EBITDA multiple of Tenaya Therapeutics? | Current EBITDA multiple of Tenaya Therapeutics is (1.1x). |
| How many companies Tenaya Therapeutics has acquired to date? | Tenaya Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Tenaya Therapeutics has invested to date? | Tenaya Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Tenaya Therapeutics
Lists including Tenaya Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.